CymaBay Therapeutics Inc. (CBAY), on Wednesday, announced new published data from a post-hoc analysis of its phase III ENHANCE study of Seladelpar demonstrating a correlation between itch cytokine interleukin-31 reduction and pruritis improvement in primary biliary cholangitis.